CA2338186C - Tumor necrosis factor-gamma - Google Patents

Tumor necrosis factor-gamma Download PDF

Info

Publication number
CA2338186C
CA2338186C CA2338186A CA2338186A CA2338186C CA 2338186 C CA2338186 C CA 2338186C CA 2338186 A CA2338186 A CA 2338186A CA 2338186 A CA2338186 A CA 2338186A CA 2338186 C CA2338186 C CA 2338186C
Authority
CA
Canada
Prior art keywords
tnf
gamma
amino acid
polypeptide
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2338186A
Other languages
English (en)
French (fr)
Other versions
CA2338186A1 (en
Inventor
Guo-Liang Yu
Jian Ni
Craig A. Rosen
Jun Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of CA2338186A1 publication Critical patent/CA2338186A1/en
Application granted granted Critical
Publication of CA2338186C publication Critical patent/CA2338186C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2338186A 1998-08-07 1999-02-08 Tumor necrosis factor-gamma Expired - Lifetime CA2338186C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/131,237 US6599719B2 (en) 1994-11-07 1998-08-07 Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha
US09/131,237 1998-08-07
PCT/US1999/002722 WO2000008139A1 (en) 1998-08-07 1999-02-08 Tumor necrosis factor-gamma

Publications (2)

Publication Number Publication Date
CA2338186A1 CA2338186A1 (en) 2000-02-17
CA2338186C true CA2338186C (en) 2011-01-25

Family

ID=22448549

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2338186A Expired - Lifetime CA2338186C (en) 1998-08-07 1999-02-08 Tumor necrosis factor-gamma

Country Status (9)

Country Link
US (1) US6599719B2 (enExample)
EP (1) EP1100886A4 (enExample)
JP (1) JP2002522041A (enExample)
KR (1) KR20010085351A (enExample)
CN (1) CN1322244A (enExample)
AU (2) AU775071B2 (enExample)
CA (1) CA2338186C (enExample)
NZ (2) NZ526411A (enExample)
WO (1) WO2000008139A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6599719B2 (en) * 1994-11-07 2003-07-29 Human Genome Sciences, Inc. Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
EP1992633A1 (en) * 1997-11-03 2008-11-19 Human Genome Sciences, Inc. VEGI, an inhibitor of angiogenesis and tumor growth
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
WO2001010908A1 (en) * 1999-08-04 2001-02-15 Amgen Inc. Ntr3, a member of the tnf-receptor supergene family
MXPA02001264A (es) * 1999-08-04 2002-07-22 Amgen Inc Fhm, nuevo miembro de la familia de supergenes de ligando de factor de necrosis tumoral.
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
CN1329024A (zh) * 2000-06-21 2002-01-02 上海博德基因开发有限公司 一种新的多肽——活化gtp酶的蛋白负调控子11.66和编码这种多肽的多核苷酸
AU2001277857A1 (en) * 2000-07-07 2002-01-21 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
WO2002047540A2 (en) * 2000-12-15 2002-06-20 The General Hospital Corporation Methods for inhibiting fibrosis
ATE466020T1 (de) 2001-11-09 2010-05-15 Univ Georgetown Neue isoform des gefässendothelzell wachstumshemmers (vegi)
US7390797B2 (en) 2002-02-28 2008-06-24 Eisai Co., Ltd. Fused indazole compounds
MXPA05006147A (es) 2002-12-10 2005-08-26 Schering Plough Ltd Ligando del activador del receptor de nf-kb de canino, y metodos para preparar y usar el mismo.
US20050075543A1 (en) * 2003-10-03 2005-04-07 Calabrese Charles A. Method of anonymous medical testing and providing the patient with the test results
US20050227920A1 (en) * 2003-12-11 2005-10-13 Xinli Lin Methods for production of recombinant vascular endothelial cell growth inhibitor
JP2005173484A (ja) * 2003-12-15 2005-06-30 Canon Inc 画像形成装置及びプロセスカートリッジ
EP2205971A4 (en) * 2007-10-04 2011-03-30 Bionomics Ltd ENDOTHEL CELL MARKERS AND USES THEREOF
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
KR20240122922A (ko) 2013-03-27 2024-08-13 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
MY191324A (en) 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
CN119735681A (zh) 2018-04-25 2025-04-01 普罗米修斯生物科学公司 优化的抗tl1a抗体
TW202600603A (zh) 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途
CN114632161B (zh) * 2020-12-16 2024-02-06 中国人民解放军军事科学院军事医学研究院 肿瘤坏死因子-α作为一种核酸基因药物体内递送载体的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
IL106271A (en) 1992-09-03 2008-03-20 Yeda Res & Dev Ligand to TNF 75P receptor and its preparation
DE69033710T2 (de) 1989-10-24 2001-06-13 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Sekretion vom mit Gamma-Interferon Signalpeptid gebundenen humänen Protein
WO1991012340A1 (en) * 1990-02-14 1991-08-22 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules
US5464938A (en) 1990-04-09 1995-11-07 Immunex Corporation Isolated viral protein TNF antagonists
US5476781A (en) * 1991-02-19 1995-12-19 University Of Florida Research Foundation, Inc. Entomopoxvirus spheroidin gene sequences
CA2114311C (en) 1991-11-25 1996-02-27 Richard Kian-Hock Wee Monoclonal wb b-cell line
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
US5891679A (en) 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
US5472856A (en) * 1993-12-21 1995-12-05 Immunobiology Research Institute, Inc. Recombinant human thymopoietin proteins and uses therefor
US6867288B1 (en) * 1994-10-12 2005-03-15 Genzyme Corporation Polycystic kidney disease gene
US6599719B2 (en) * 1994-11-07 2003-07-29 Human Genome Sciences, Inc. Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha
JP4046349B2 (ja) 1994-11-07 2008-02-13 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 腫瘍壊死因子−γ
WO1996040774A1 (en) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical preparations
EP1992633A1 (en) * 1997-11-03 2008-11-19 Human Genome Sciences, Inc. VEGI, an inhibitor of angiogenesis and tumor growth
MXPA02001264A (es) * 1999-08-04 2002-07-22 Amgen Inc Fhm, nuevo miembro de la familia de supergenes de ligando de factor de necrosis tumoral.

Also Published As

Publication number Publication date
US6599719B2 (en) 2003-07-29
EP1100886A4 (en) 2003-06-18
KR20010085351A (ko) 2001-09-07
CA2338186A1 (en) 2000-02-17
WO2000008139A1 (en) 2000-02-17
AU2593499A (en) 2000-02-28
AU775071B2 (en) 2004-07-15
EP1100886A1 (en) 2001-05-23
JP2002522041A (ja) 2002-07-23
US20030027284A1 (en) 2003-02-06
AU2004203451A1 (en) 2004-08-26
CN1322244A (zh) 2001-11-14
NZ526411A (en) 2005-01-28
NZ509560A (en) 2003-08-29

Similar Documents

Publication Publication Date Title
AU775071B2 (en) Tumor necrosis factor-gamma
AU753157B2 (en) VEGI, an inhibitor of angiogenesis and tumor growth
US20020150534A1 (en) Tumor necrosis factor-gamma
CA2343655C (en) Interleukin 17-like receptor protein
US6261801B1 (en) Nucleic acids encoding tumor necrosis factor receptor 5
AU708972B2 (en) Tumor necrosis factor-gamma
US8093363B2 (en) Tumor necrosis factor-gamma
PT970213E (pt) Receptor 5 contendo um domínio de morte
CA2248868A1 (en) Apoptosis inducing molecule ii
US20020111325A1 (en) VEGI, an inhibitor of angiogenesis and tumor growth
US20030129189A1 (en) Tumor necrosis factor-gamma
US6824767B2 (en) Tumor necrosis factor-gamma
EP1054968A1 (en) Apoptosis inducing molecule ii and methods of use
WO2000066608A9 (en) Tumor necrosis factor-gamma
MXPA01001426A (en) Tumor necrosis factor-gamma
AU2003200047B2 (en) VEGI, An Inhibitor of Angiogenesis and Tumor Growth
EP1114142A1 (en) Interleukin 17-like receptor protein
KR19990087832A (ko) 사람의종양괴사인자델타및엡실론

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20190208